バーレーン - 英語 - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain & bahrain pharmacy co - diclofenac, diclofenac sodium - suppository - 12.5

アラブ首長国連邦 - 英語 - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

5's blister -

ナミビア - 英語 - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - diclofenac sodium - suppository - 12,5 mg/suppository

ナミビア - 英語 - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - diclofenac sodium - suppository - 25 mg/suppository

ナミビア - 英語 - Namibia Medicines Regulatory Council

novartis south africa (pty) ltd - diclofenac sodium - suppository - 50 mg/suppository

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium -

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

unit dose services - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. voltaren® gel is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation risk summary use of nsaids, including voltaren® gel, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including voltaren® gel, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of voltaren® gel in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a backgrou

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. voltaren® gel is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation risk summary use of nsaids, including voltaren® gel, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including voltaren® gel, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of voltaren® gel in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

endo pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. voltaren gel is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation risk summary use of nsaids, including voltaren gel, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including voltaren gel, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of voltaren gel in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - voltaren gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren gel has not been evaluated for use on the spine, hip, or shoulder. voltaren gel is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions ( 5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.7, 5.8)] . - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions ( 5.1 ) ] pregnancy category c prior to 30 weeks